DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
M•••• • A•••••••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Also written as: Equity Securities
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
101¢ · 101¢Q4 2025 to Q1 2026
Principal held
at least $8.0M
sum of BDC pieces, a lower bound
Fair value
$8.0M
101c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
2
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
May 3, 2029
no dated debt inside 24 months
On the tape since
Jun 30, 2023
latest Mar 31, 2026
Events
2
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| A•••• P•••••• C••••• F•••• L•• | $7.98M | 101¢ | 0 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| A•••• P•••••• C••••• F•••• L•• | term loan first lien Investment T••• U••••••••• I•••••• T••• L••• I•••• S+ S••••• 5.00% I••••••• R••• 8.68% A•• | $8.0M | $8.0M 101c | SOFR+500 bp |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Mar 31, 2026 | at least $8.0M | 101c | SOFR+500 bp | May 3, 2029 | 1 |
Equity pieces beside the debt: equity ($310,620 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2026 | 1 | $8.0M | $8.0M | 101c | 0 |
| Dec 31, 2025 | 1 | $16.0M | $16.0M | 101c | 0 |
| Sep 30, 2024 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2024 | 1 | $0 | $0 | n/a | 0 |
All 8 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2023 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2023 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2023 | 1 | $0 | $0 | n/a | 0 |
What changed
- Facility left every BDC scheduleMar 31, 2026
- New borrower on a BDC scheduleJun 30, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- MINDS AND ASSEMBLYderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 2 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it